209 related articles for article (PubMed ID: 22453016)
1. Metastatic uveal melanoma: biology and emerging treatments.
Woodman SE
Cancer J; 2012; 18(2):148-52. PubMed ID: 22453016
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE
Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035
[TBL] [Abstract][Full Text] [Related]
3. GZ17-6.02 kills PDX isolates of uveal melanoma.
Booth L; Roberts JL; Spasojevic I; Baker KC; Poklepovic A; West C; Kirkwood JM; Dent P
Oncotarget; 2024 May; 15():328-344. PubMed ID: 38758815
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem-like cells in uveal melanoma: novel insights and therapeutic implications.
Loda A; Semeraro F; Parolini S; Ronca R; Rezzola S
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189104. PubMed ID: 38701937
[TBL] [Abstract][Full Text] [Related]
5. Tumor Characteristics, Genetics, Management, and the Risk of Metastasis in Uveal Melanoma.
Nichols EE; Richmond A; Daniels AB
Semin Ophthalmol; 2016; 31(4):304-9. PubMed ID: 27128983
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound-enhanced nano catalyst with ferroptosis-apoptosis combined anticancer strategy for metastatic uveal melanoma.
Wang Q; He J; Qi Y; Ye Y; Ye J; Zhou M
Biomaterials; 2024 Mar; 305():122458. PubMed ID: 38211370
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma.
Buchbinder EI; Cohen JV; Tarantino G; Lian CG; Liu D; Haq R; Hodi FS; Lawrence DP; Giobbie-Hurder A; Knoerzer D; Sullivan RJ
Cancer Res Commun; 2024 May; 4(5):1321-1327. PubMed ID: 38683104
[TBL] [Abstract][Full Text] [Related]
8. Quercetin Impairs the Growth of Uveal Melanoma Cells by Interfering with Glucose Uptake and Metabolism.
Tura A; Herfs V; Maaßen T; Zuo H; Vardanyan S; Prasuhn M; Ranjbar M; Kakkassery V; Grisanti S
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673877
[TBL] [Abstract][Full Text] [Related]
9. Activation of NFAT by HGF and IGF-1 via ARF6 and its effector ASAP1 promotes uveal melanoma metastasis.
Richards JR; Shin D; Pryor R; Sorensen LK; Sun Z; So WM; Park G; Wolff R; Truong A; McMahon M; Grossmann AH; Harbour JW; Zhu W; Odelberg SJ; Yoo JH
Oncogene; 2023 Aug; 42(35):2629-2640. PubMed ID: 37500798
[TBL] [Abstract][Full Text] [Related]
10. Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.
Al Balushi K; Al Hadhrami A; Balushi HA; Al Lawati A; Das S
Curr Drug Targets; 2024; 25(3):149-157. PubMed ID: 38115619
[TBL] [Abstract][Full Text] [Related]
11. Mouse models of uveal melanoma: Strengths, weaknesses, and future directions.
Richards JR; Yoo JH; Shin D; Odelberg SJ
Pigment Cell Melanoma Res; 2020 Mar; 33(2):264-278. PubMed ID: 31880399
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Immune interactions: implications for cancer therapy.
Tham M; Abastado JP
Cell Cycle; 2015; 14(9):1347-8. PubMed ID: 25894850
[No Abstract] [Full Text] [Related]
13. Beneath the surface: a case report of metastatic iridociliary ring melanoma treated with pembrolizumab.
Parra-Bernal C; Aguilera-Partida JA; Dalvin LA; Rodríguez-Reyes AA; Ancona-Lezama D
Arq Bras Oftalmol; 2024; 86(5):e20230046. PubMed ID: 35319657
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma.
Fahmy LM; Schreidah CM; McDonnell DE; Carvajal RD; Magro CM; Geskin LJ
Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478664
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights.
Rodriguez I; Norman T; Guenther J; Smart K; Kwong A; Berry J; In GK; Worswick S
Clin Exp Dermatol; 2024 Mar; 49(4):392-394. PubMed ID: 37956104
[No Abstract] [Full Text] [Related]
16. Treatment of uveal melanoma: where are we now?
Yang J; Manson DK; Marr BP; Carvajal RD
Ther Adv Med Oncol; 2018; 10():1758834018757175. PubMed ID: 29497459
[TBL] [Abstract][Full Text] [Related]
17. Improving therapy in metastatic uveal melanoma by understanding prior failures.
Olson DJ; Luke JJ
Oncoscience; 2020 May; 7(5-6):40-43. PubMed ID: 32676517
[No Abstract] [Full Text] [Related]
18. YAP as oncotarget in uveal melanoma.
Yu FX; Zhang K; Guan KL
Oncoscience; 2014; 1(7):480-1. PubMed ID: 25594048
[No Abstract] [Full Text] [Related]
19. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK
JAMA; 2014 Jun; 311(23):2397-405. PubMed ID: 24938562
[TBL] [Abstract][Full Text] [Related]
20. Uveal melanoma: From diagnosis to treatment and the science in between.
Chattopadhyay C; Kim DW; Gombos DS; Oba J; Qin Y; Williams MD; Esmaeli B; Grimm EA; Wargo JA; Woodman SE; Patel SP
Cancer; 2016 Aug; 122(15):2299-312. PubMed ID: 26991400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
